BiPar At The Center Of Sanofi's Efforts To Rebuild Its Oncology Business
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III PARP inhibitor for triple-negative breast cancer leads Sanofi's efforts to restock its oncology pipeline.
You may also be interested in...
Sanofi's PARP Inhibitor Plus Chemo May Be A Lethal One-Two Punch In Triple-Negative Breast Cancer
News that Sanofi-Aventis' PARP inhibitor iniparib conferred "significant clinical benefit" in a proof of concept study against metastatic triple-negative breast cancer – published online Jan. 5 by the New England Journal of Medicine – has generated excitement about the approach, but a Phase III study powered for statistically meaningful results in overall and progression-free survival will tell the tale.
Sanofi's PARP Inhibitor Plus Chemo May Be A Lethal One-Two Punch In Triple-Negative Breast Cancer
News that Sanofi-Aventis' PARP inhibitor iniparib conferred "significant clinical benefit" in a proof of concept study against metastatic triple-negative breast cancer – published online Jan. 5 by the New England Journal of Medicine – has generated excitement about the approach, but a Phase III study powered for statistically meaningful results in overall and progression-free survival will tell the tale.
Sanofi Bulks Up Oncology Development With Avila Collaboration
Sanofi-Aventis adds to its expertise in oncology by striking a deal with Massachusetts-based Avila Therapeutics for the biotech's covalent-bonding technology in a deal that could be worth up to $800 million.